Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Irinotecan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 6/20 | 0.77 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.99 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.99 |
| ▸ | GLA | P06280 | 2/20 | 0.99 |
| ▸ | GAA | P10253 | 2/20 | 0.99 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.99 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.99 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.99 |
| ▸ | MMP1 | P03956 | 1/20 | 0.99 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.99 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.99 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.99 |
| ▸ | ACHE | P22303 | 1/20 | 0.99 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.99 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.99 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | HPGD | P15428 | 1/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Irinotecan SCHEMBL31175855 | 1.00 | PAX8 (0.99) | PAX8NCOA3GLAGAASLC22A2 | |
| Irinotecan SCHEMBL29359605 | 0.99 | PAX8 (1.00) | PAX8NCOA3GLAGAASLC22A2 | |
| Irinotecan SCHEMBL572716 | 0.99 | PAX8 (1.00) | PAX8NCOA3GLAGAASLC22A2 | |
| Irinotecan SCHEMBL30822976 | 0.99 | PAX8 (1.00) | PAX8NCOA3GLAGAASLC22A2 | |
| Irinotecan SCHEMBL359364 | 0.99 | PAX8 (1.00) | PAX8NCOA3GLAGAASLC22A2 | |
| Irinotecan SCHEMBL12313065 | 0.99 | GLA (1.00) | PAX8NCOA3GLAGAASLC22A2 | |
| Irinotecan SCHEMBL13420262 | 0.99 | GLA (1.00) | PAX8NCOA3GLAGAASLC22A2 | |
| Irinotecan SCHEMBL131381 | 0.99 | GLA (1.00) | PAX8NCOA3GLAGAASLC22A2 | |
| Irinotecan SCHEMBL4034 | 0.99 | GLA (1.00) | PAX8NCOA3GLAGAASLC22A2 | |
| Irinotecan SCHEMBL19534323 | 0.99 | GLA (1.00) | PAX8NCOA3GLAGAASLC22A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101337966-A | Method for preparing high-purity irinotecan | JIANGSU HENGRUI MEDICINE CO (CN) | 2009-01-07 | — | — | CN | claimed |
| EP-3337478-B2 | DRUG COMBINATION COMPRISING LIPOSOMAL IRINOTECAN, OXALIPLATIN, 5-FLUOROURACIL AND LEUCOVORIN FOR TREATING METASTATIC PANCREATIC CANCER | IPSEN BIOPHARM LTD (GB) | 2026-03-04 | — | — | EP | disclosed |
| US-20250381191-A1 | Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin | IPSEN BIOPHARM LTD. (GB) | 2025-12-18 | — | — | US | disclosed |
| US-20250333396-A1 | INHIBITING ATAXIA TELANGIECTASIA AND RAD3-RELATED PROTEIN (ATR) | CELATOR PHARMACEUTICALS INC (US) | 2025-10-30 | — | — | US | disclosed |
| US-20240358706-A1 | Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin | IPSEN BIOPHARM LTD. (GB) | 2024-10-31 | — | — | US | disclosed |
| CN-116211803-B | Inhibiting ataxia telangiectasia and Rad3 associated protein (ATR) | 赛莱特制药公司 | 2024-10-11 | — | — | CN | disclosed |
| EP-4438127-A2 | INHIBITING ATAXIA TELANGIECTASIA AND RAD3-RELATED PROTEIN (ATR) | Celator Pharmaceuticals, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| EP-3936153-B1 | INHIBITING ATAXIA TELANGIECTASIA AND RAD3-RELATED PROTEIN (ATR) | CELATOR PHARMACEUTICALS INC (US) | 2024-08-21 | — | — | EP | disclosed |
| US-20230416236-A1 | INHIBITING ATAXIA TELANGIECTASIA AND RAD3-RELATED PROTEIN (ATR) | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE | 2023-12-28 | — | — | US | disclosed |
| US-11787781-B2 | Inhibiting ataxia telangiectasia and RAD3-related protein (ATR) | CELATOR PHARMACEUTICALS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| EP-3535026-A1 | TREATING GASTRIC CANCER USING COMBINATION THERAPIES COMPRISING LIPOSOMAL IRINOTECAN, OXALIPLATIN, 5-FLUORURACIL (AND LEUCOVORIN) | Ipsen Biopharm Limited (GB) | 2019-09-11 | — | — | EP | disclosed |
| CN-101337966-B | Method for preparing high-purity irinotecan | JIANGSU HENGRUI MEDICINE CO | 2011-05-18 | — | — | CN | disclosed |
| CN-101337966-A | Method for preparing high-purity irinotecan | JIANGSU HENGRUI MEDICINE CO (CN) | 2009-01-07 | — | — | CN | disclosed |
| EP-1331005-B1 | MEDICINAL COMPOSITIONS FOR CONCOMINANT USE AS ANTICANCER ATENT | EISAI CO LTD (JP) | 2006-04-05 | — | — | EP | disclosed |
| CN-1196484-C | Pharmaceutical composition used in combination as anticancer agent | EISAI CO LTD (JP) | 2005-04-13 | — | — | CN | disclosed |
| US-20040224972-A1 | Medicinal compositions for concomitant use as anticancer agent | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-11-11 | — | — | US | disclosed |
| CN-1473041-A | Medical compositions for concominant use as anticancer atent | ������������ʽ���� | 2004-02-04 | — | — | CN | disclosed |
| US-20040002505-A1 | Medicinal compositions for cocominant use as anticancer agent | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-01-01 | — | — | US | disclosed |
| US-20030215523-A1 | Medicinal compositions for concomitant use as anticancer agent | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-11-20 | — | — | US | disclosed |
| EP-1331005-A1 | MEDICINAL COMPOSITIONS FOR CONCOMINANT USE AS ANTICANCER ATENT | Eisai Co., Ltd. (JP) | 2003-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224972-A1 | Medicinal compositions for concomitant use as anticancer agent | MTDH, TOP2B, TOP1 | TOP1 3/4885PAX8 2194/4885NCOA3 824/4885 |
| US-20250333396-A1 | INHIBITING ATAXIA TELANGIECTASIA AND RAD3-RELATED PROTEIN (ATR) | ATR, CHEK2, CHEK1 | TOP1 121/4885PAX8 3332/4885NCOA3 1048/4885 |
| US-20230416236-A1 | INHIBITING ATAXIA TELANGIECTASIA AND RAD3-RELATED PROTEIN (ATR) | ATR, CHEK2, CHEK1 | TOP1 121/4885PAX8 3332/4885NCOA3 1048/4885 |
| US-11787781-B2 | Inhibiting ataxia telangiectasia and RAD3-related protein (ATR) | ATR, CHEK2, CHEK1 | TOP1 121/4885PAX8 3332/4885NCOA3 1048/4885 |
| US-20030215523-A1 | Medicinal compositions for concomitant use as anticancer agent | MTDH, TOP2B, TOP1 | TOP1 3/4885PAX8 2194/4885NCOA3 824/4885 |
| US-20040002505-A1 | Medicinal compositions for cocominant use as anticancer agent | MTDH, TOP2B, CCNH | TOP1 6/4885PAX8 3475/4885NCOA3 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.